These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. Murphy JR; Baqar S; Davis JR; Herrington DA; Clyde DF J Clin Microbiol; 1989 Jul; 27(7):1434-7. PubMed ID: 2671011 [TBL] [Abstract][Full Text] [Related]
47. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria. Webster HK; Ho M; Looareesuwan S; Pavanand K; Wattanagoon Y; Warrell DA; Hockmeyer WT Am J Trop Med Hyg; 1988 Jan; 38(1):37-41. PubMed ID: 3277463 [TBL] [Abstract][Full Text] [Related]
48. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Charoenvit Y; Collins WE; Jones TR; Millet P; Yuan L; Campbell GH; Beaudoin RL; Broderson JR; Hoffman SL Science; 1991 Feb; 251(4994):668-71. PubMed ID: 1704150 [TBL] [Abstract][Full Text] [Related]
50. Tandem use of PCR and synthetic peptides to map helper T-cell epitopes on 27-kDa sexual stage antigen of Plasmodium falciparum. Koski GK; Ploton IN; Viscidi R; Kumar N Pept Res; 1996; 9(3):127-35. PubMed ID: 8875592 [TBL] [Abstract][Full Text] [Related]
51. Malaria vaccine development using synthetic peptides as a technical platform. Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780 [TBL] [Abstract][Full Text] [Related]
52. Differential recognition of Plasmodium falciparum merozoite surface protein 2 variants by antibodies from malaria patients in Brazil. Kanunfre KA; Leoratti FM; Hoffmann EH; Durlacher RR; Ferreira AW; Moraes-Avila SL; Ferreira MU Clin Diagn Lab Immunol; 2003 Sep; 10(5):973-6. PubMed ID: 12965937 [TBL] [Abstract][Full Text] [Related]
53. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. Sim BK; Orlandi PA; Haynes JD; Klotz FW; Carter JM; Camus D; Zegans ME; Chulay JD J Cell Biol; 1990 Nov; 111(5 Pt 1):1877-84. PubMed ID: 2229177 [TBL] [Abstract][Full Text] [Related]
54. High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Thomas AW; Trape JF; Rogier C; Goncalves A; Rosario VE; Narum DL Am J Trop Med Hyg; 1994 Dec; 51(6):730-40. PubMed ID: 7810805 [TBL] [Abstract][Full Text] [Related]
56. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698 [TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910 [TBL] [Abstract][Full Text] [Related]
58. Plasmodium berghei subunit vaccine: repeat synthetic peptide of circumsporozoite protein comprising T- and B-cell epitopes fails to confer immunity. Migliorini P; Boulanger N; Betschart B; Corradin G Scand J Immunol; 1990 Feb; 31(2):237-42. PubMed ID: 1689867 [TBL] [Abstract][Full Text] [Related]
59. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum. Enders B; Hundt E; Knapp B Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721 [TBL] [Abstract][Full Text] [Related]
60. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]